JT001

• Description:

  JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1].

• Product Name Alternative:

  NLRP3-IN-19

• UNSPSC:

  12352005

• Target:

  NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jt001.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NS(=O)(C1=C2OCCCN2N=C1)=O)NC3=C4CCCC4=CC5=C3CCC5

• Molecular Formula:

  C19H22N4O4S

• Molecular Weight:

  402.47

• References & Citations:

  [1]Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386 (2) :242-258.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  NLRP3

• CAS Number:

  [2238819-65-1]